News and Events

"Over 120M patients suffer from osteoarthritis (OA) worldwide. There is no cure. Theragen is focused on finding the cure"

Theragen LLC acquires Neurotech NA

August 14, 2015, Theragen LLC acquired Neurotech NA and its global assets from Bio-Medical Research LTD (Galway, Ireland). The acquisition includes the Kneehab XP® quadriceps neuromuscular stimulation product cleared for the reeducation and strengthening of muscles, commonly referred to as muscle atrophy, and associated with injury and during pre- and post-surgical total knee replacement procedures….

Theragen LLC expands executive leadership ranks

Theragen LLC announces the addition of J. Chris McAuliffe to its executive team, September 01, 2014. Mr. McAuliffe will assume the role of Executive Vice President and COO. Gary Grenter, President & CEO said; “We are pleased that Chris made the decision to join the Theragen Team. He has significant domain experience in non-invasive electrical…

Theragen LLC secures worldwide license for non-invasive treatment of Osteoarthritis

July 2014, Theragen LLC announces the completion of a worldwide exclusive licensing agreement to develop and commercialize a novel, non-invasive Capacitive Coupling (CC) electrical stimulation technology for treatment of Osteoarthritis (OA). The CC signal, developed by Dr. Carl Brighton and researchers at the University of Pennsylvania shows promise in the regeneration of articular cartilage. The…